

Product datasheet for TR309253

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

SMAD4 Human shRNA Plasmid Kit (Locus ID 4089)

Product data:

Product Type: shRNA Plasmids

Product Name: SMAD4 Human shRNA Plasmid Kit (Locus ID 4089)

Locus ID:

DPC4; JIP; MADH4; MYHRS Synonyms:

Vector: pRS (TR20003)

E. coli Selection: Ampicillin Mammalian Cell

Selection:

Puromycin

Format: Retroviral plasmids

SMAD4 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = Components:

4089). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

NM 005359, NM 005359.1, NM 005359.2, NM 005359.3, NM 005359.4, NM 005359.5, RefSeq:


BC002379, BC002379.2, BM701399, NM 005359.6

UniProt ID: O13485

Summary: This gene encodes a member of the Smad family of signal transduction proteins. Smad

> proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The protein acts as a tumor suppressor and inhibits epithelial cell proliferation. It may also have an inhibitory effect on tumors by reducing angiogenesis and increasing blood vessel hyperpermeability. The encoded protein is a crucial component of the bone morphogenetic protein signaling pathway. The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and

hereditary hemorrhagic telangiectasia syndrome. [provided by RefSeq, Aug 2017]





shRNA Design:

These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).